Ropes & Gray Advises CD&R in its Investment in M2GEN
Ropes & Gray acted as legal advisor to Clayton, Dubilier & Rice ("CD&R") funds in connection with its investment in M2GEN. The financial terms of the transaction, which was announced on March 17, were not disclosed. The press release is here.
Merck GHI and McKesson Ventures invested alongside CD&R funds, and collectively become the company's largest shareholder in M2GEN. Existing shareholders Moffitt Cancer Center, Hearst Healthcare, and The Ohio State University Foundation continue to hold a significant minority interest in M2GEN.
M2GEN is a leading oncology data and informatics platform focused on transforming cancer care. Clayton, Dubilier & Rice, a private investment firm with offices in New York and London, has managed the investment of more than $30 billion in 98 companies with an aggregate transaction value of more than $150 billion.
The Ropes & Gray team representing CD&R was led by private equity partner>s Carolyn Vardi (New York) and Scott Abramowitz (New York), and included health care partner David Peloquin (Boston), life sciences regulatory & compliance partner Albert Cacozza (Washington D.C.), IP transactions partner Megan Baca (Silicon Valley), mergers & acquisitions partner Michael Beauvais (Boston), employment, executive compensation & employment partners Allie Alperovich (New York) and Megan Bisk (Boston), and tax partner Adam Greenwood (New York).